Clinical Trial Update: Confirmatory Study of Topical HyBryte™ vs. Placebo for the Treatment of CTCL [Phase 3]

View source ↗

Summary

A Phase 3 confirmatory study of topical HyBryte versus placebo for cutaneous T-cell lymphoma (CTCL) is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous T-cell Lymphoma
• Mycosis Fungoides

Drugs mentioned

• HyBryte (synthetic hypericin)

Snippet

Sponsor: Soligenix | Conditions: CTCL/ Mycosis Fungoides, CTCL | Phase 3 | Status: RECRUITING